Product/Composition:- | Atezolizumab |
---|---|
Strength:- | 1200 mg/20 mL |
Form:- | Intravenous infusion |
Reference Brands:- | Tecentriq® (EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Atezolizumab (Tecentriq®) is a PD-L1 checkpoint inhibitor used in urothelial carcinoma, NSCLC, and triple-negative breast cancer. Available as sterile IV infusion vials (1200 mg/20 mL), manufactured under EU-GMP and USFDA standards. Ideal for B2B supply, hospital tenders, and licensing.
Atezolizumab (Tecentriq®) is a PD-L1 immune checkpoint inhibitor indicated for urothelial carcinoma, NSCLC, and triple-negative breast cancer. Provided as sterile intravenous infusion vials (1200 mg/20 mL), Atezolizumab is produced under EU-GMP and USFDA standards. Offered for B2B supply, contract manufacturing, and licensing, it supports hospital tenders and oncology distributors with full regulatory documentation. This monoclonal antibody restores anti-tumor immunity by blocking PD-L1, making it a vital immuno-oncology therapy in US and European cancer treatment portfolios.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications